You started the medication because nothing else had worked. And it is working — the scale is moving, the food noise is quieter, your clothes fit differently. But somewhere around month two or three, a new worry creeps in: how much of what you’re losing is fat, and how much is the muscle you’ll wish you’d kept? And the bigger question nobody at the pharmacy counter mentions — what happens when you eventually come off?
Here’s the honest version, start to finish. GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound are powerful tools, but they change your body composition and your relationship with food in ways that need managing — both while you’re on them and after. This guide walks through the whole arc: what’s happening in your body now, how to protect what matters, and how to hold onto your results when the medication stops.
What GLP-1 medications actually do
GLP-1 (glucagon-like peptide-1) receptor agonists work by mimicking a hormone your gut already makes. They slow how fast your stomach empties, blunt appetite, and quiet the constant background chatter about food. The result is a sharp drop in how much you eat — and, for most people, significant weight loss. In the STEP 1 trial, the study behind semaglutide’s approval for weight management, participants lost an average of about 17% of their body weight over 68 weeks [2].
But rapid weight loss is rarely only fat. When the weight comes off fast on a sharply reduced appetite, a meaningful share of it can be lean mass — muscle, not just fat. That’s the central body-composition problem of the GLP-1 era: the medication makes losing weight easier than it’s ever been, which is exactly why protecting muscle now takes intention it never used to.
The muscle problem — and why it matters more than the scale
Muscle isn’t just about looking toned. It’s metabolically active tissue: it helps regulate blood sugar after meals, it’s a major driver of your resting metabolic rate, and it’s what keeps you strong and functional as you age. Lose too much of it and you weaken the very engine that keeps weight off — which sets up the rebound that catches so many people later.
The numbers are real. A review in Circulation notes that semaglutide has been associated with lean-mass loss of up to about 40% of total weight lost, and in the STEP 1 trial specifically, roughly 45% of the weight lost was lean mass [3]. Whether that loss meaningfully harms long-term health is still being studied — but the prudent move, especially if you want to keep your results, is to protect muscle rather than hope you’re in the lucky group.
Three things do that work while you’re losing weight on a GLP-1: getting enough protein (harder than it sounds when your appetite is suppressed), resistance training to signal your body to hold the muscle it has, and losing weight at a pace your body can tolerate. We break down how each one works, and the common mistakes that quietly cost you lean mass, in our deep dive on why you’re losing muscle on Ozempic — and the 3 things that stop it.
The protein piece is the hard part. When the medication has flattened your appetite, hitting a protein target that preserves muscle can feel impossible — you’re full after a few bites. That gap between what your body needs and what you can comfortably eat is exactly what our GLP-1 Nutrition Companion was built to close: how to structure meals, reach your protein without forcing volume, and eat in a way that protects muscle while the medication does its work.
What happens when you stop
This is the part most people don’t plan for until they’re in it. GLP-1 medications manage appetite while you take them — they don’t permanently reset it. When you come off, the suppression fades, the food noise can return, and without a plan the weight tends to follow.
The evidence is consistent across studies. Pooling data from multiple trials, researchers at the University of Cambridge found that people regain on average about 60% of their lost weight within a year of stopping — though the regain then tends to plateau, leaving many people still holding onto roughly a quarter of what they originally lost [1]. The landmark STEP 1 trial extension showed the same pattern at the higher end, with participants regaining about two-thirds of their lost weight and their cardiometabolic improvements drifting back toward baseline [2]. The throughline: obesity behaves like a chronic condition, and holding the results generally takes an ongoing plan rather than a finish line.
That sounds like a sentence, but it isn’t one. The regain is the default — what happens in the absence of a transition strategy, not a fate written into the drug. The people who hold their results treat coming off as its own phase with its own plan. The first 30 days are the critical window, and a handful of specific, well-meaning mistakes drive most of the regain. We lay out the day-by-day reality and how to avoid each one in the hidden truth about quitting Ozempic: 5 weight-loss mistakes women make.
If you’re approaching that transition — or already in it — Off the Pen is the step-by-step plan for the come-off: how to reset your expectations, rebuild the habits the medication was handling for you, and protect your results once the appetite suppression is gone.
The two stages are one journey
Here’s the thing worth seeing clearly: protecting muscle on the medication and keeping your results off it aren’t separate problems. They’re the same problem at two stages. The muscle you preserve while losing weight is the metabolic engine that makes maintenance possible later. The eating habits you build now are the ones you’ll lean on when the medication is no longer quieting your appetite. Do the first stage well and the second gets far easier.
That’s why we put both guides together. The GLP-1 Library — Complete Bundle gives you the complete system — the on-medication nutrition strategy and the coming-off transition plan — so you’re not solving each stage from scratch as you reach it. The whole arc, start to finish, in one place. See the complete GLP-1 Library →
Frequently asked questions
Will I lose muscle on Ozempic or Wegovy?
Some lean-mass loss accompanies any rapid weight loss, including on GLP-1 medications, unless you actively protect against it — in the STEP 1 trial, around 45% of the weight lost was lean mass [3]. The three levers that help most are adequate protein, resistance training, and a sustainable pace of loss. Here’s how each one works.
How much protein do I need on a GLP-1 medication?
Protein needs rise when you’re losing weight and trying to preserve muscle — but the medication’s appetite suppression makes hitting that target genuinely hard. The skill is structuring meals to get the protein in without forcing large volumes of food, which is the focus of the GLP-1 Nutrition Companion.
Will I regain the weight when I stop?
On average, people regain about 60% of their lost weight within a year of stopping, though the regain tends to plateau after that [1]. But that’s the default outcome without a transition plan, not a guarantee. Treating the come-off as its own phase, with its own strategy, is what separates the people who keep their results from those who don’t.
Should I take a GLP-1 medication at all?
That’s a decision for you and your prescribing doctor. This guide isn’t medical advice and doesn’t weigh in on whether to start, switch, or stop a medication — it’s about protecting your body and your results whatever you and your doctor decide.
This article is for general education and isn’t a substitute for medical care. GLP-1 medications are prescription drugs; decisions about starting, changing, or stopping them should be made with your prescribing clinician.
Sources
- Patients regain weight rapidly after stopping weight loss drugs — but still keep off a quarter of weight lost. University of Cambridge, 2026. cam.ac.uk
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. NCBI
- Muscle mass and GLP-1 receptor agonists: adaptive or maladaptive response to weight loss? Circulation, 2024. AHA Journals